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Background: In determining the level of bone resection in Ewing sarcoma, the most suitable time at which to perform
magnetic resonance imaging (MRI) remains controversial. Current guidelines recommend that surgical planning be based
on MRI performed prior to neoadjuvant chemotherapy. The goal of this study was to determine whether pre-chemotherapy
or post-chemotherapy MRI provides greater accuracy of tumor limits for planning bone excision in the management of
Ewing sarcoma.
Methods: This was a single-center, retrospective study. MRI was performed using 3 sequences: T1-weighted,
T1-weighted with contrast enhancement by gadolinium injection, and a fluid-sensitive sequence (STIR [short tau inversion
recovery] or proton-density-weighted with fat saturation). The tumor extent as assessed on pre-chemotherapy and post-
chemotherapy MRI was compared with histological measurement of the resected specimen.
Results: Twenty patients with Ewing sarcoma of a long bone were included. In 6 cases, the tumor was located on the
femur, in 5, the tibia; in 5, the fibula; and in 4, the humerus. The median patient age at diagnosis was 9.7 years. We found
greater accuracy of measurements from MRI scans acquired after chemotherapy than from those acquired before che-
motherapy. For both pre-chemotherapy and post-chemotherapy MRI, the greatest accuracy was achieved with the non-
enhanced T1 sequence. There was no benefit to gadolinium enhancement. The median difference between T1 MRI and
histological measurements was 19.0 mm (interquartile range [IQR], 4.3 to 32.8 mm) before chemotherapy and 5.0 mm
(IQR, 2.0 to 13.0 mm) after chemotherapy. Adding a minimum margin of 20 mm to the limit of the tumor on post-
chemotherapy T1 MRI always led to safe histological margin.
Conclusions: Post-chemotherapy MRI provided a more accurate assessment of the limits of Ewing sarcoma. Surgical
planning can therefore be based on post-chemotherapy MRI. Surgical cuts can be, at minimum, 20 mm from the limits as
seen on MRI.
E
wing sarcoma is the second-most common type of
malignant bone tumor in children1. Conventional
treatment includes neoadjuvant chemotherapy, local
treatment, and adjuvant chemotherapy. Local treatment
may consist of surgical resection and/or radiation therapy2.
When possible, resection within healthy margins seems
preferable to radiation therapy alone3,4. Enneking5 defined
resection areas as “radical,” “wide,” “marginal,” and “in-
tralesional.” Because of the importance of neoadjuvant
chemotherapy in reducing the size of the tumor, the re-
quired size of the margins has come under reconsideration.
The issue remains controversial in the literature. In a review
of 244 patients, Ozaki et al. found no significant difference
between adequate (radical and wide) and inadequate
(marginal and intralesional) margins with respect to the
local relapse rate and overall survival after surgery6. In a
review of 64 patients, Lin et al. assessed local control ac-
cording to whether the margins were 0 to 2 mm, 3 to 9 mm,
or ‡10 mm7. They found a trend toward better local control
with wider as opposed to narrower margins, although this
did not reach significance.
Magnetic resonance imaging (MRI), by improving the
assessment of tumor limits8, is the gold standard for plan-
ning surgical margins. During the treatment of Ewing sar-
coma, 3 MRI studies are generally performed: the first, at
diagnosis, before the start of neoadjuvant chemotherapy; the
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second, during the course of chemotherapy; and the third, at
the end of neoadjuvant chemotherapy, before local treat-
ment. The intraosseous signal anomalies found on MRI may
be related to tumor development but also to perilesional
inflammation. Neoadjuvant chemotherapy can alter the
signals of both the inflammation and tumor regions, but to
an extent that is not known. It also remains unknown
whether bone resection should be carried out at the level
defined on the initial pre-chemotherapy MRI or as defined
on the post-chemotherapy MRI, with the latter typically
supporting a lesser and better defined resection. The current
recommendation is to decide the limits of surgical resection
using pre-chemotherapy MRI9,10 to avoid the risk of con-
taminated resection margins.
The primary objective of this study was to determine
which MRI study was more reliable for determining tumor
extent: MRI performed pre-neoadjuvant chemotherapy or
performed post-neoadjuvant chemotherapy. The secondary
objective was to determine the most suitable MRI sequence.
We compared the assessment of tumor limits on pre-
chemotherapy and post-chemotherapy MRI with the limits
as evaluated on histological analysis of the resected
specimen.
Materials and Methods
This was a single-center, retrospective study including pa-tients treated for Ewing sarcoma of a long bone between
March 2005 and June 2015. Excluded were patients with a bone
resection margin that was contaminated (classified as R1 or
R2), because histological tumor limits could not be deter-
mined, or those with a pathological fracture, because the
modification of bone orientation could result in noncompa-
rable radiographic measurements.
An analysis of pre-chemotherapy and post-chemotherapy
MRI scans was performed in a standardized manner by a senior
radiologist. Three sequences were studied: T1-weighted, T1-
weighted with contrast enhancement by gadolinium injection,
and a fluid-sensitive sequence (STIR [short tau inversion re-
covery] or proton-density-weighted with fat saturation [PD
fat-sat]) (Fig. 1). For each sequence, we determined the tumor
extent as delineated by abnormal compared with normal signal
on the coronal sections.We considered that it was not possible to
determine the difference between edema and tumor by MRI
signal changes, so we therefore included all signal abnormalities.
Once the tumor extent was determined, we measured the dis-
tance between the proximal and distal limits of the abnormal
signal within the bone and the corresponding bone end (Figs. 2-
A and 2-B). The extension into the soft tissues was not part of the
evaluation. These MRI measurements were performed for the
study and were independent from the measurements used for
surgical planning.
Histological analysis was performed by an experienced
bone-tumor pathologist. We defined the limits of the tumor as
the area beyond which the tissue was normal, i.e., without
necrotic tumor and without a scar area that could contain
tumor stigma as foamymacrophages or fibrous regions. On the
resected specimen, we measured the distance between the tu-
mor limits (proximal and distal) and the corresponding bone
Fig. 1
Ewing sarcoma of the left femur in an 11-year-old boy, as demonstrated on pre-chemotherapy T1-weighted MRI (Fig. 1-A), post-chemotherapy T1-weighted
MRI (Fig. 1-A’), pre-chemotherapy STIR MRI (Fig. 1-B), post-chemotherapy STIR MRI (Fig. 1-B’), pre-chemotherapy T1-weighted MRI with gadolinium
enhancement (Fig. 1-C), and post-chemotherapy T1-weighted MRI with gadolinium enhancement (Fig. 1-C’).
ends. When the end included the epiphysis, this histological
measurement was sufficient. When the end was a bone cut, we
added to the histological measurement the distance between
the bone cut and the end of the residual bone as measured on
postoperative computed radiography. The sum of these 2 dis-
tances corresponded to the distance of the tumor relative to the
bone end (Fig. 2-C).
To evaluate MRI accuracy in determining the tumor
limit, we chose to study the difference between each MRI
measurement and the reference histological measurement.
Thus, this difference was not dependent on bone length. Values
were scored negative when the MRI limit was in a healthy zone
relative to the histological limit and were scored positive when
the MRI limit was within the tumor area.
Statistical Analysis
For descriptive analyses, we report frequencies and percentages for
categorical variables and themedian and interquartile range (IQR)
for quantitative variables. We used the 1-sample Wilcoxon paired
test to compare the results between pre-chemotherapy and post-
chemotherapy. The concordance between values of the different
measures was assessed using Bland and Altman plots and Spear-
man correlation coefficients. Analyses were performed using R
software (version 3.0.1; R Foundation for Statistical Computing).
Results
Twenty-two patients with Ewing sarcoma of a long bonewere initially included. However, 2 patients were ex-
cluded, 1 because of a pathological fracture and 1 because of
an intralesional resection (R2). In the latter case, pre-
chemotherapy and post-chemotherapy MRI showed signal
abnormalities where the surgical cut was made. It was
therefore not a failure of MRI to identify the tumor limits. We
analyzed the data of 20 patients, 15 children and 5 adults, with
a median age at diagnosis of 9.7 years (range, 3 to 38 years). In
6 cases, the tumor was located on the femur; in 5, the fibula;
in 5, the tibia; and in 4, the humerus. In some cases, mea-
surements were not feasible for all of the sequences studied
because of the quality of the images. Thus, of the 40 possible
measurements for each sequence at each MRI assessment
period, we report measurements from 38 T1, 36 STIR,
and 36 T1 1 gadolinium-enhanced sequences from pre-
chemotherapy MRI and 39 T1, 35 STIR, and 39 T1 1
gadolinium-enhanced sequences from post-chemotherapy
MRI. The median duration between pre-chemotherapy MRI
and surgery was 161 days (range, 93 to 315 days). The median
duration between post-chemotherapy MRI and surgery was
13 days (range, 1 to 60 days).
Table I lists the difference between the MRI measurement
(distance between the signal abnormalities and the corre-
sponding bone end) and the histological measurement (distance
between the proximal or distal extent of the tumor and the
corresponding bone end) by MRI sequence for each patient.
We compared the distribution of the absolute values of
these differences for all sequences studied and found greater
accuracy of the measurements made using post-chemotherapy
MRI compared with pre-chemotherapy MRI (Table II). The
greatest accuracy was found for the nonenhanced T1
Fig. 2
Ewing sarcomaof the left tibia in an 8-year-old boy. Fig. 2-A Pre-chemotherapy T1-weightedMRI. The distance between the proximal end of the bone and the
proximal limit of the tumor (x) and the distance between the distal end of the bone and the distant limit of the tumor (x’) are indicated. Fig. 2-B Post-
chemotherapy T1-weighted MRI. The distance between the proximal end of the bone and the proximal limit of the tumor (y) and the distance between the
distal end of the bone and the distant limit of the tumor (y’) are indicated. Fig. 2-C Histological measurements are shown. In this case, the proximal (z) and
distal (z’) measurements represent the distance between the respective tumor limit and the bone cut on the surgical specimen added to length of the
residual bone as measured on computed radiograph.
TABLE I Difference Between MRI Measurement and Histological Measurement, by MRI Sequence*
Difference (mm)
Pre-Chemotherapy Post-Chemotherapy
Patient Age (yr) T1 STIR T1 1 Gado. T1 STIR T1 1 Gado.
1 10 Proximal 223 222 222 213 215 215
Distal 28 228 234 24 24 24
2 6 Proximal 220 224 224 28 212 26
Distal 221 234 235 28 27 211
3 10 Proximal 25 211 3 1 0
Distal 229 236 215 213 29
4 5 Proximal 242 246 241 236 234 232
Distal 24 21 22 2 1 1
5 11 Proximal 213 269 262 21 22 24
Distal 213 213 246 26 25 28
6 9 Proximal 22 211 23 24 23 22
Distal 4 27 3 1 2 1
7 9 Proximal 21 0 2 4 22 4
Distal 241 230 226 214 212 7
8 3 Proximal 233 229 235 21 214 210
Distal 267 277 275 218 225 216
9 6 Proximal 25 28 25 22 22
Distal 20 215 2 1 210
10 8 Proximal 276 276 278 0 1 0
Distal 263 263 261 15 15 15
11 13 Proximal 212 29 28 28
Distal 234 224 217 218
12 38 Proximal 232 238 240 221 218 221
Distal 226 219 228 225 222 222
13 14 Proximal 1 245 248 0 212 25
Distal
14 4 Proximal 232 242 242 28 213 220
Distal 218 217 219 0 24 21
15 9 Proximal 25 27 28 22 0 0
Distal 234 289 281 249 257 257
16 8 Proximal 224 234 234 28 27 25
Distal 274 271 249 6 27 29
17 24 Proximal 2 222 220 25 28 27
Distal 218 218 210 213 211 215
18 27 Proximal 2 220 26 21 24 219
Distal 22 22 22 22 22 22
19 23 Proximal 0 23 27 0 1 1
Distal 60 53 51 25 28 214
20 32 Proximal 22 22 22 22 22 22
Distal 234 228 242
*Difference between the MRI measurement (distance between the signal abnormalities and the corresponding bone end) and the histological
measurement (distance between the proximal or distal extent of the tumor and the corresponding bone end) for each MRI sequence. STIR = short
tau inversion recovery, and gado. = gadolinium.
sequences. There seemed to be no benefit from the addition of
a contrast medium.
We then conducted a categorical analysis of the differ-
ences between MRI and histological measurements, with the
differences categorized as follows: £210 mm, >210 to 0 mm,
and >0 mm (Table III). For each MRI sequence, we also report
the minimum and maximum difference between the MRI and
histological measurements.
Using a threshold of 210 mm, the categorical analysis
demonstrated a trend similar to that of an analysis of the average
of the absolute values: values of £210 mmwere more common
for the pre-chemotherapy measurements. MRI limits within the
tumor area were slightly more common for the post-
chemotherapy measurements but with much lower maximum
values than for the pre-chemotherapy measurements (15 mm
post-chemotherapy compared with values ranging from 51 to
60 mm pre-chemotherapy). On pre-chemotherapy MRI, the
overvaluation of the tumor limits was sometimes important, up
to 76 mm for the T1 sequence, with 4 values of >50 mm. In 2
cases, there was an underestimation corresponding to tumor
progression during the course of chemotherapy (Fig. 3). On
post-chemotherapy MRI, the underestimation of the tumor
limits was always £15 mm.
Finally, we report the results as Bland and Altman plots,
which demonstrate greater accuracy of post-chemotherapy
TABLE II Quantitative Analysis of Differences between MRI and Histological Measurements
Absolute Value of Difference* (mm)
Pre-Chemotherapy Post-Chemotherapy P Value
MRI sequence
T1 (n = 38) 19.0 (4.3-32.8) 5.0 (2.0-13.0) <0.0001
STIR (n = 34) 26.0 (11.5-44.3) 7.0 (2.0-13.0) <0.0001
T1 1 gadolinium (n = 36) 25.0 (6.8-43.0) 7.5 (2.0-15.0) <0.0001
*The values are given as the median with the interquartile range in parentheses.
TABLE III Categorical Analysis of Differences Between MRI and Histological Measurements
£210 mm >210 to 0 mm >0 mm
Min./Max. Difference (mm)
No. % No. % No. %
Pre-chemotherapy
T1 (n = 38) 22 58% 10 26% 6 16% 276/60
STIR (n = 36) 27 75% 8 22% 1 3% 289/53
T1 1 gadolinium (n = 36) 23 64% 9 25% 4 11% 281/51
Post-chemotherapy
T1 (n = 39) 11 28% 21 54% 7 18% 249/15
STIR (n = 35) 14 40% 15 43% 6 17% 257/15
T1 1 gadolinium (n = 39) 15 38% 18 46% 6 15% 257/15
Fig. 3
Ewing sarcoma of the left femur in a 23-year-old woman. Fig. 3-A Pre-
chemotherapy T1-weighted MRI. Fig. 3-B Post-chemotherapy T1-weighted
MRI, showing obvious tumor progression during the course of chemotherapy.
assessment (Fig. 4). The Spearman correlation coefficients for
the MRI-based measurements in relation to the histological
measurements were high: before chemotherapy, 0.96 for T1,
0.94 for STIR, and 0.94 for T1 1 gadolinium enhancement;
and after chemotherapy, 0.98, 0.98 and 0.99, respectively
(p < 0.0001 for all).
There were epiphyseal signal abnormalities in 12 cases
on pre-chemotherapy MRI, and in 8 of those cases, abnormal
signal persisted on post-chemotherapy MRI. However,
pathological evaluation revealed epiphyseal extension of the
tumor in only 2 of the 8 cases; in the remaining 6 cases, no
epiphyseal abnormality was observed. Among the 4 cases in
which the anomaly of epiphyseal signal was normalized on
post-chemotherapy MRI, 1 resection with epiphyseal preser-
vation was carried out, with R0 margins on pathological
evaluation. This would not have been possible with surgical
cuts planned according to pre-chemotherapy MRI (Fig. 5). In
the 3 other cases, the epiphyseal bone pathology was strictly
normal.
No local recurrence was diagnosed in any of the patients
included in this study at the time of the latest follow-up (mean
follow-up of 68 months; range, 24 to 111 months).
Fig. 4
BlandandAltmanplotsofMRI-basedmeasurements comparedwithmeasurementsmadebyananatomopathologist (AP). The continuous red line indicates
the average difference (diff) between the considered MRI measurements and histological measurements. The dashed red lines indicate 2 standard
deviations above and below the average difference.
Discussion
We found excellent correlation between MRI and histo-logical analysis in the assessment of tumor limits. Similar
results were presented by Panuel et al.11. Their study included 22
children (5 with Ewing sarcoma and 17 with osteosarcoma).
Pathological analyses were compared withMRI performed up to
3 weeks before surgery. A transphyseal extension was evident on
MRI in 13 cases (12 of the 17 patients with osteosarcoma and
1 of the 5 with Ewing sarcoma), which corresponded in all cases
to an extension found histologically. There were no false-positive
or false-negative cases. They recommended using primarily T1
sequences. Bloem et al.8 compared the length of the tumor as
measured on MRI with that of the histological specimen for 56
patients (including 27 with osteosarcoma, 14 with chondrosar-
coma, and 10 with Ewing sarcoma). MRI measurements were
acquired using T1 and T2 sequences; the timing of MRI in re-
lation to neoadjuvant chemotherapy was not specified. The
correlation coefficient was 0.99. The most precise type of se-
quence was not investigated.
The current study validates the use of post-
chemotherapy MRI to determine the tumor limits during
the planning of bone cuts in the management of Ewing sar-
coma. We found that the best sequence to determine the tu-
mor limits was T1-weighted. Our results did not show any
benefit of gadolinium enhancement. STIR sequences over-
estimated tumor limits because of their susceptibility to in-
flammatory abnormalities. These results are similar to those
of Panuel et al.11. In our series, growth-plate signal abnor-
malities on pre-chemotherapy MRI disappeared after che-
motherapy in 4 cases. This allowed surgery preserving the
epiphysis in 1 case (Fig. 5).
Planning the resection using post-chemotherapy MRI
allows for the possibility of tumor progression during the
course of chemotherapy. In the case of progression, planning
based on pre-chemotherapy MRI may lead to an incomplete
resection. In our series, pre-chemotherapy MRI undervalued
the tumor limit for 2 patients, with a difference of 20 mm for
one and 60 mm for the other (Fig. 3). Similarly, there is
sometimes a period of several weeks between the initial MRI
and the beginning of chemotherapy, particularly when a
problem of biopsy analysis arises. The tumor may progress in
the meantime. Again, the initial MRI may undervalue the
length of the bone segment to be resected.
Our study had limitations. This was a retrospective study,
with a small number of cases (n = 20). However, this did not
prevent the demonstration of significant differences between
pre-chemotherapy and post-chemotherapy MRI measure-
ments (Table II). In this study, we dealt only with bone limits.
Therefore, our results do not suggest on which MRI to base
planning regarding the extension to soft tissues. In addition, we
chose not to analyze the tumor limit on MRI in the sagittal
plane because we thought that measurements were less
Fig. 5
Ewing sarcoma of the right femur in a 3-year-old girl. Fig. 5-A Pre-chemotherapy T1-weighted MRI, showing epiphyseal signal abnormalities. Fig. 5-B Post-
chemotherapy T1-weightedMRI, showing complete normalization of epiphyseal signal. Fig. 5-C Radiographmade 3 years after surgery. The epiphysis was
preserved with healthy margins.
reproducible than in the coronal plane and that it would not
dramatically improve accuracy. Finally, the time when the MRI
was performed was variable, which may have affected the ac-
curacy of the measurements.
We chose to study only Ewing sarcoma and not osteo-
sarcoma, as inflammatory peri-tumor phenomena vary be-
tween the 2 types. They are often more important in Ewing
sarcoma, which makes the choice of resection limits more
difficult. These non-mass-like areas with abnormal MR signal
intensity are often qualified as inflammation or edema.
However, we know that there may be tumor cells in those
areas. Masrouha et al.12 reported on 30 cases (27 osteosarcoma
and 3 Ewing sarcoma) in which they found that 17.4% of these
areas were positive for tumor (viable or necrotic). That is why
we included all signal abnormalities in the MRI analysis.
Improving the accuracy of the assessment of tumor
limits can permit reduction of safety margins. The objective is
to expand the possibilities for epiphyseal conservation, for
better durability of function of the reconstructed limb. Be-
cause of the possibility of the presence of tumor cells away
from the main tumor, it seems necessary to maintain a margin
beyond the limit suggested by post-chemotherapy MRI. We
recommend a minimum margin of 20 mm, which, in our
series, always allowed a resection in a healthy area. This rec-
ommendation is valid when there is no anatomical barrier
separating the resection limit from the tumor. However, it can
probably be further reduced when there is an anatomical
barrier such as the physis. Previous studies showed the ca-
pacity of the physis to act as a barrier, limiting tumor exten-
sion13,14, although it can sometimes be crossed11. It is
important to underline that the objective of the present study
was to correlate MRI with histological evaluation, not to de-
termine the amount of margin necessary. Despite there being
no local recurrence among our patients, additional studies are
needed to highlight prognostic factors.
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In summary, the results of our study contradict the
conventional recommendation: the determination of
Ewing sarcoma bone tumor limits as assessed on post-
chemotherapy MRI seems more accurate than limits as-
sessed on pre-chemotherapy MRI. We therefore recommend
planning for bone excision in Ewing sarcoma using post-
chemotherapy MRI.
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